No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 42, Issue 12, 2002, Pages 1358-1365

  Anderson, Denise M ^a   Shelley, Sarah ^b   Crick, Nina ^a   Buraglio, Mauro ^c  

^a Ajinomoto Pharmaceut Europe Limited   (United Kingdom)

^b GCP Management Services Limited   (United Kingdom)

^c LCG Bioscience   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PROTHROMBIN; REPAGLINIDE; SULFONYLUREA; WARFARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ANALYSIS OF VARIANCE; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOHEXANES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PHENYLALANINE; PROTHROMBIN TIME; TIME FACTORS; WARFARIN;

EID: 0036890920     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002238772     Document Type: Article

References (25)

1. Koch-Weser J, EM Sellars: Drug interactions with coumarin anticoagulants. N Engl J Med 1971;285:487-498, 547-558.
2. Kikuchi M: Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A-4166. Diabetic Med 1996;13(9, suppl. 6):S151-S155.
3. Ikenoue T, Akiyoshi M, Fulitani S, Okazaki K, Kondo N, Maki T: Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent (-)-N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166). Br J Pharmacol 1997;120:137-145.
4. Whitelaw DC, Clark PM, Smith JM, Nattrass M: Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes. Diabetic Med 2000;17:225-229.
5. Takesada H, Matsuda K, Ohtake R, Mihara R, Ono I, Tanaka K, Naito M, Yatagai M, et al: Structure determination of metabolites isolated from urine and bile after administration of AY-4166, a novel D-phenylalanine-derivative hypoglycaemic agent. Bioorg Med Chem 1996;4:1771-1781.
6. Karara AH, Dunning BE, McLeod JF: The effect of food on the oral bioavailability and the pharmacodynamic actions on the insulinotropic actions of the agent nateglinide in healthy subjects. J Clin Pharmacol 1999;39:172-179.
7. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF: Single dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol 2000;40:634-640.
8. Dunn CJ, Faulds D: Nateglinide. Drugs 2000;60:607-615.
9. Chan E, MaLachlan A, O'Reilly R, Rowland M: Stereochemical aspects of warfarin drug interaction: Use of a combined pharmacokineticpharmacodynamic model. Clin Pharmacol Ther 1994;56:286-294.
10. Ono I, Matsuda K, Kanno S: Determination of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine in human plasma by solid-phase extraction and column-switching high performance liquid chromatography with ultraviolet detection. J Chromatog B 1996;678:384-387.
11. Banfield C, Rowland M: Stereospecific fluorescence high-performance liquid chromatography analysis of R- and (S)-warfarin and its metabolites in plasma and urine. J Pharm Sci 1984;73: 1392-1396.
12. Mercer S, Anderson D: The effect of timing of food on the pharmacokinetics and pharmacodynamics of nateglinide (for type 2 diabetes) and the effect of nateglinide on the gastric emptying rate. AAPS PharmSci 1999;1(suppl.):A2084.
13. Anderson DM, Shelley S, Crick N, Buraglio M: A three-way cross over study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. Int J Clin Pharm Ther 2002;40:457-464.
14. Koch-Weser J, Sellers EM: Drug interactions with coumarin anticoagulants. N Engl Med 1971;285:547-558.
15. Niopas I, Toon S, Aarons L, Rowland M: The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Eur J Clin Pharmacol 1999;55:399-404.
16. Weber C, Banken L, Birnboeck H, Schultz R: Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999;39: 847-854.
17. Zhi J, Melia AT, Guerciolini R, Koss-Twardy SG, Passe SM, Rakhit A, Sadowski JA: The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996;36:659-666.
18. Pitsiu M, Parker EM, Aarons L, Rowland M: Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci 1993;1:151-157.
19. Center for Drug Evaluation and Research: Guidance for Industry Food-Effect Bioavailability and Bioequivalence Studies: Draft Guidance for Industry. Rockville, MD, U.S. Department of Health and Human Services, Food and Drug Administration, October 1997.
20. Toon S, Hopkins KJ, Garstang FM, Rowland M: Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharm 1987;32: 165-172.
21. Reynolds JEFE: Martindale: The Extra Pharmacopoeia. 30th Ed. London: The Pharmaceutical Press, 1993.
22. Kalbag JB, Walter YH, Nedelman JR, McLeod JF: Mealtime glucose regulation with nateglinide in healthy volunteers. Diabetes Care 2001;24:73-77.
23. Hanefeld M, Dickinson S, Bouter KP, Guitard C: Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycaemia. Diabetes Care 2000;23:202-207.
24. Turck D, Su CAPF, Heinzel G, Busch U: Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997;51:421-425.
25. Kong AT, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995;35:1008-1015.